Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of hepatocellular carcinoma (HCC) according to the European Association for the Study of the Liver (EASL) criteria~  * Advanced disease~ * Must be morphologically evaluable~* HCC not accessible to other treatment (e.g., surgery, radiofrequency, or chemoembolization) and can not benefit from antiangiogenic therapy~* CLIP score ≤ 3 (except for patients with tumors invading more than 50% of tumor volume)~* Child-Pugh cirrhosis score between B7 and B9, meeting the following criteria:~  * Diagnosed clinically, biologically (e.g., prothrombin time, platelets, or albumin), endoscopically (signs of portal hypertension) and morphologically (dysmorphic liver on ultrasound or CT scan), or by liver biopsy~* Not a candidate for transplantation and has not received a liver transplant~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Platelet count ≥ 50,000/mm\^3~* Neutrophil count ≥ 1,500/mm\^3~* Creatinine clearance ≥ 60 mL/min~* GFR ≥ 30 mL/min~* Serum cholesterol ≤ 350 mg/dL~* Triglycerides ≤ 300 mg/dL~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for more than 2 months after completion of study therapy~* No history of other cancer on treatment~* No cardiopulmonary disease impairment, including a history of stable or unstable angina or myocardial infarction~* No active infection except for viral hepatitis~* No HIV positivity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior inhibitors or inducers of P-glycoprotein, CYP3A4, or CYP3A5~* At least 4 weeks since prior surgery, radiotherapy (except radiotherapy to the bone), transarterial chemoembolization, immunotherapy, or other investigational drug for HCC~* At least 6 months since prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: OTHER): Temsirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).